Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Completed · Phase 1/Phase 2
Conditions studied: Leukemia, Myelodysplastic Syndromes
In brief
RATIONALE: Peripheral stem cell transplantation may be an effective treatment for leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia that has relapsed following bone marrow transplantation. PURPOSE: Phase I/II trial to study the effectiveness of decitabine and peripheral stem cell transplantation in treating patients who have leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia that has relapsed after bone marrow transplantation.
Key facts
- Study ID
- NCT00002832
- Run by
- M.D. Anderson Cancer Center
- People needed
- 14
- Starts
- 1995-08-01
- Expected to finish
- 2002-03-01
- Last updated by the study team
- 2012-07-30
Who can join
Age: any, up to 60. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.